Investigating a metabolic pathway in kidney disease for targeted therapies
Official title: GSTM1-Transsulfuration metabolic axis in kidney disease: therapeutic target in precision medicine
Funded at University of Rochester · NIH-11060042 · Data updated 2026-11-12
This study is looking at how a missing enzyme called GSTM1 might make kidney disease worse, and it aims to find new treatment options for people with chronic kidney disease by exploring how this enzyme affects important processes in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | March 21, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $597,511 |
| NIH project number | 5R01DK136064-02 |
| Project ID | NIH-11060042 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals, particularly African Americans, who are genetically predisposed to GSTM1 deficiency and are experiencing chronic kidney disease.
✕Less likely to help
Patients without GSTM1 deficiency or those with kidney disease unrelated to this metabolic pathway may not benefit from this research.
What this research studies
This research focuses on the role of the GSTM1 enzyme in kidney disease, particularly how its deficiency may lead to faster progression of chronic kidney disease (CKD). The study examines the metabolic pathways influenced by GSTM1, including the balance of hydrogen sulfide, which is crucial for cell metabolism and signaling. By understanding these mechanisms, the research aims to identify potential therapeutic targets for precision medicine in patients with kidney disease, especially among those with specific genetic backgrounds. The approach includes both animal models and human population studies to validate findings.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatments for kidney disease that improve patient outcomes and slow disease progression.
How similar studies have gone: Previous studies have shown associations between GSTM1 deficiency and increased risks of kidney disease, suggesting that this research builds on established findings rather than exploring entirely novel territory.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Le, Thu H. — University of Rochester
- Study coordinator: Le, Thu H.
Related research
Other NIH-funded projects on the same topics.
-
Personalized CKD-MBD care using systems biology and AI
A patient-facing program aims to tailor mineral-balance therapy for people with chronic kidney disease by using a computer model and smart decision rules to predict who will respond best to treatments.
-
Mitigating DKA in people with type 1 diabetes and kidney disease using SGLT1/2 inhibitors
This project tests a new way to prevent dangerous diabetic ketoacidosis in people with type 1 diabetes and chronic kidney disease who are using SGLT inhibitors, by tracking ketones in real time and combining glucose-keton data for safer therapy.
-
Chronic Kidney Disease in Children: following young people as they grow up with CKD
A long-term study in kids with chronic kidney disease tracks kidney function and heart health as they transition into adulthood.
-
Chronic Kidney Disease in Children follow-up study
A long-term study that follows kids with kidney disease as they grow into young adults, collecting health data from home and official records.
-
KDARC: Building a research backbone to study aging and kidney disease
Aimed at creating a dedicated infrastructure to advance aging-related kidney disease research so clinicians can better care for older adults.
-
Malaria-related kidney injury and its link to chronic kidney disease in children
This grant looks at why some children who have malaria develop kidney injury and later chronic kidney disease, focusing on how severe malaria affects the kidneys over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.